LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today will present an update from its ongoing open label, long-term extension study of the investigational medicine CTP ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented initial data from the ongoing long-term, open-label extension study of the investigational medicine ...
Lexington, MA -- Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results